Tunlametinib is an oral MEK1/2 inhibitor that has demonstrated synergistic antitumor activity when combined with the BRAF inhibitor vemurafenib in early clinical studies of BRAF-mutant cancers. Recognizing its potential, China's NMPA granted Breakthrough Therapy Designation in December 2024 to the tunlametinib–vemurafenib combination for previously treated patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). If approved, tunlametinib would become the first MEK inhibitor specifically indicated for this patient population, addressing a significant unmet need. Building on this momentum, the latest Phase III results presented at ASCO 2026 further support the combination's potential to improve outcomes for patients with BRAF V600E-mutant mCRC.

Efficacy results:

• Median Progression-Free Survival (PFS): 4.2 months with tunlametinib plus vemurafenib .vs 1.5 months with investigator’s choice therapy (HR: 0.374; p < 0.001).

• Objective Response Rate (ORR): 37.1% with tunlametinib + vemurafenib vs. 7.7% in the control arm (p < 0.0001).

• Disease Control Rate (DCR): 81.9% with tunlametinib + vemurafenib vs. 38.5% with investigator’s choice (p < 0.0001).

• Overall Survival (OS): Data were immature at the time of analysis.

Safety results:

• Grade ≥3 treatment-related adverse events (TRAEs): 62.0% in the tunlametinib + vemurafenib arm vs. 44.2% in the control arm.

• Permanent treatment discontinuation due to TRAEs: 0.9% with tunlametinib + vemurafenib vs. 3.8% with investigator’s choice therapy.

• Safety profile consistent with the known safety profiles of tunlametinib and vemurafenib, with no new safety signals reported.

KOL insights

“The preliminary results show that tunlametinib and vemurafenib provided clinically meaningful improvements in investigator-assessed efficacy outcomes for previously treated patients with BRAF-mutant metastatic colorectal cancer. The combination demonstrates a manageable safety profile, consistent with the known safety profiles of each individual drug, offering a new, all-oral treatment option for this high-need population.” –Expert Opinion

“Tunlametinib plus vemurafenib demonstrated significant improvements in progression-free survival and objective response rates compared with investigator-selected therapy in previously treated patients with BRAF V600E-mutant mCRC.” Expert Opinion

Conclusion

Patients with BRAF V600E-mutant mCRC continue to face limited treatment options and unfavorable outcomes, underscoring a significant unmet need in China. The positive Phase III findings for tunlametinib plus vemurafenib reinforce the promise of precision oncology in this setting. Supported by its Breakthrough Therapy Designation from China's NMPA, the combination has the potential to become the first MEK inhibitor-based regimen approved for BRAF V600E-mutant mCRC in China.

Despite entering a competitive landscape dominated by BRAFTOVI-based regimens and other biomarker-driven therapies, tunlametinib plus vemurafenib differentiates itself through its all-oral administration, strong efficacy, and manageable safety profile. The positive ASCO 2026 results position the combination as a promising new contender in BRAF V600E-mutant mCRC, with the potential to expand treatment options and intensify competition in the targeted CRC market.